Biotechnology · Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
- Last close
- $165.04 +5.4%
- 52-week range
- $149.18 to $479.79
- Market cap
- $22.1B
- Next earnings
- Not scheduled
Fiscal 2025 at a glance
Stock price
Valuation vs its own 10 years
Where each multiple sits today inside its own range since 2016, measured at every quarter end. The thin tick is the median.
Key statistics
Trailing 12 months unless noted, through the quarter ending 2026-09-30. Every figure carries its unit.
Valuation
- P/E
- n/aNo earnings
- Earnings yield
- n/a
- Price / sales
- n/a
- Price / book
- 6.1x
- Price / operating cash flow
- n/a
- EV / EBITDA
- n/a
- EV / sales
- n/a
- Free cash flow yield
- n/a
n/a: Not reported
Profitability
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- Return on equity
- 73.5%
- Return on capital
- n/a
n/a: Not reported
Growth per year
- Revenue, 3 years
- +53.0%
- Revenue, 5 years
- +49.8%
- Revenue, 9 years
- +62.4%
- EPS, 3 years
- n/aNot meaningful (a loss in the window)
Balance sheet
- Cash and investments
- $3.59B
- Total debt
- n/a
- Net cash
- $3.59B
- Debt / equity
- n/a
- Current ratio
- 2.48x
n/a: No debt reported
Shares and dividend
- Shares outstanding
- 134M
- Share count, 5 years
- +17.1%
- Beta, 1 year
- 0.54
- Dividend yield
- n/a
- Dividend per share, TTM
- n/a
- Payout ratio
- n/a
n/a: No dividend
Ten years of the business
Last 40 quarters, fiscal 2016 to 2025 and after. Hover a bar for its quarter.
Fiscal years 2016 to 2025.
Where the revenue comes from
Amvuttra went from 9% to 62% of revenue in 3 years
Share of revenue by product line, fiscal 2022 to 2025, as reported in the 10-K.
| Product line | Revenue | Share | vs FY24 |
|---|---|---|---|
| Amvuttra | $2.31B | 62.3% | +138% |
| Collaborations | $553M | 14.9% | +8% |
| GIVLAARI | $308M | 8.3% | +21% |
| OXLUMO | $191M | 5.2% | +15% |
| Royalty | $174M | 4.7% | +90% |
| ONPATTRO | $173M | 4.7% | -32% |
Biotechnology peers
The largest names in the same industry that we cover, all in US dollars. The last column applies the same history test to each peer.
| Company | Market cap | Revenue growth | Operating margin | P/E | P/S | P/E vs own history |
|---|---|---|---|---|---|---|
| ONC BeOne Medicines Ltd. | $619B | +33% | 17.8% | 689x | 93.6x | Not enough history |
| ABBV AbbVie Inc. | $521B | +11% | 32.2% | 50.8x | 7.9x | 72nd percentile |
| AMGN Amgen Inc | $252B | +8% | 32.4% | 27.0x | 6.5x | 78th percentile |
| GILD Gilead Sciences, Inc. | $208B | +7% | -7.6% | No earnings | 6.7x | No earnings |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137B | +10% | 33.2% | 34.7x | 10.5x | 71st percentile |
| ALNY Alnylam Pharmaceuticals, Inc. | $22.1B | n/a | n/a | No earnings | n/a | No earnings |
The company
- Sector
- Health Care
- Industry
- Biotechnology
- Founded
- 2002
- Headquarters
- Cambridge, MA
- Fiscal year ends
- December
- Website
- alnylam.com
What it does
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Description from Wikipedia (CC BY-SA).
Around the numbers
What the rest of EdgeStacker knows about ALNY.